Grifols S.A Total Liabilities

Latest as of December 2025: €12.11 Billion EUR ≈ $14.16 Billion USD

Grifols S.A total liabilities. Based on the latest financial reports, Grifols S.A (G0FB) has total liabilities worth €12.11 Billion EUR (≈ $14.16 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Grifols S.A to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Grifols S.A (2016–2025)

Total liabilities of Grifols S.A from 2016 to 2025. This chart illustrates how Grifols S.A's total liabilities have evolved over time, based on quarterly financial data. Explore Grifols S.A (G0FB) long-term investment share to see how much of total assets are deployed in long-term investments.

Grifols S.A Competitors by Total Liabilities

The table below lists competitors of Grifols S.A ranked by their total liabilities.

Company Country Total Liabilities
Jiangxi Copper Company Limited
F:JIX
Germany €162.37 Billion
Softcat plc
F:SF5
Germany €919.96 Million
SICC Co. Ltd.
SHG:688234
China CN¥2.32 Billion
Yonyou Network Technology Co Ltd
SHG:600588
China CN¥12.54 Billion
EPR Properties
NYSE:EPR
USA $3.74 Billion
ENTAIN PLC UNSP.ADR/1
F:6GI0
Germany €7.91 Billion
HYBE Co. Ltd
KO:352820
Korea ₩2.16 Trillion
Zhejiang Crystal Optech Co Ltd
SHE:002273
China CN¥3.44 Billion

Liability Composition Analysis (2016–2025)

This chart breaks down Grifols S.A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Grifols S.A total assets.

Liquidity & Leverage Metrics

Grifols S.A Total Liabilities Ratios Explained

Grifols S.A total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 2.51 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 2.30 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.61 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Grifols S.A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Grifols S.A (2016–2025)

The table below shows the annual total liabilities of Grifols S.A from 2016 to 2025.

Year Total Liabilities Change
2025-12-31 €12.11 Billion
≈ $14.16 Billion
-5.39%
2024-12-31 €12.80 Billion
≈ $14.96 Billion
-5.05%
2023-12-31 €13.48 Billion
≈ $15.76 Billion
+3.07%
2022-12-31 €13.08 Billion
≈ $15.29 Billion
+17.95%
2021-12-31 €11.09 Billion
≈ $12.96 Billion
+29.60%
2020-12-31 €8.55 Billion
≈ $10.00 Billion
-1.63%
2019-12-31 €8.70 Billion
≈ $10.17 Billion
+11.78%
2018-12-31 €7.78 Billion
≈ $9.10 Billion
+6.78%
2017-12-31 €7.29 Billion
≈ $8.52 Billion
+13.82%
2016-12-31 €6.40 Billion
≈ $7.48 Billion
--

About Grifols S.A

F:G0FB Germany Drug Manufacturers - General
Market Cap
$5.57 Billion
€4.76 Billion EUR
Market Cap Rank
#3733 Global
#692 in Germany
Share Price
€7.00
Change (1 day)
-0.71%
52-Week Range
€5.95 - €8.35
All Time High
€22.14
About

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, … Read more